To Örebro University

oru.seÖrebro University Publications
Change search
Link to record
Permanent link

Direct link
Alternative names
Publications (10 of 19) Show all publications
Vumma, R., Ellsworth, Z., Bumford, K., Venizelos, N. & Montero, J. (2025). Mechanisms of Proinflammatory Cytokines in the Progression of Neuropsychiatric Disorders. Journal of Pharmacology and Experimental Therapeutics, 392(3), Article ID 101049.
Open this publication in new window or tab >>Mechanisms of Proinflammatory Cytokines in the Progression of Neuropsychiatric Disorders
Show others...
2025 (English)In: Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, E-ISSN 1521-0103, Vol. 392, no 3, article id 101049Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
Elsevier, 2025
National Category
Pharmacology and Toxicology
Identifiers
urn:nbn:se:oru:diva-120667 (URN)10.1016/j.jpet.2024.101049 (DOI)001462483500010 ()
Available from: 2025-04-22 Created: 2025-04-22 Last updated: 2025-08-06Bibliographically approved
Vumma, R., Rode, J., Yang, L., Montero, J., König, J., Wall, R., . . . Rangel, I. (2024). Exploring Therapeutic Strategies for Neuropsychiatric Disorders: Modulating Inflammation, Gut-Brain Interactions, and the Role of Butyrate. Paper presented at ASPET 2024 Annual Meeting - Neuropharmacology, Arlington, VA, USA, May 16-19, 2024.. Journal of Pharmacology and Experimental Therapeutics, 387(S3), Article ID 336.127906.
Open this publication in new window or tab >>Exploring Therapeutic Strategies for Neuropsychiatric Disorders: Modulating Inflammation, Gut-Brain Interactions, and the Role of Butyrate
Show others...
2024 (English)In: Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, E-ISSN 1521-0103, Vol. 387, no S3, article id 336.127906Article in journal, Meeting abstract (Refereed) Published
Place, publisher, year, edition, pages
American Society for Pharmacology and Experimental, 2024
Keywords
Neuropsychiatric Disorders
National Category
Psychiatry
Research subject
Psychiatry
Identifiers
urn:nbn:se:oru:diva-114769 (URN)10.1124/jpet.336.127906 (DOI)
Conference
ASPET 2024 Annual Meeting - Neuropharmacology, Arlington, VA, USA, May 16-19, 2024.
Available from: 2024-07-12 Created: 2024-07-12 Last updated: 2025-08-11Bibliographically approved
Tabrisi, R., Harun-Rashid, M. D., Johansson, J., Venizelos, N. & Msghina, M. (2023). Clozapine but not lithium reverses aberrant tyrosine uptake in patients with bipolar disorder. Psychopharmacology, 240(8), 1667-1676
Open this publication in new window or tab >>Clozapine but not lithium reverses aberrant tyrosine uptake in patients with bipolar disorder
Show others...
2023 (English)In: Psychopharmacology, ISSN 0033-3158, E-ISSN 1432-2072, Vol. 240, no 8, p. 1667-1676Article in journal (Refereed) Published
Abstract [en]

RATIONALE: Availability of the dopamine and noradrenaline precursor tyrosine is critical for normal functioning, and deficit in tyrosine transport across cell membrane and the blood-brain barrier has been reported in bipolar disorder and schizophrenia. Clozapine and lithium are two psychoactive agents used to treat psychosis, mood disorders and suicidal behavior, but their mechanism of action remains largely unknown.

OBJECTIVE: To characterize immediate and delayed differences in tyrosine uptake between healthy controls (HC) and bipolar patients (BP) and see if these differences could be normalized by either clozapine, lithium or both. A second objective was to see if clozapine and lithium have additive, antagonistic or synergistic effects in this.

METHOD: Fibroblasts from five HC and five BP were incubated for 5 min or 6 h with clozapine, lithium, or combination of both. Radioactive labelled tyrosine was used to quantify tyrosine membrane transport.

RESULTS: There was significantly reduced tyrosine uptake at baseline in BP compared to HC, a deficit that grew with increasing incubation time. Clozapine selectively increased tyrosine uptake in BP and abolished the deficit seen under baseline conditions, while lithium had no such effect. Combination treatment with clozapine and lithium was less effective than when clozapine was used alone.

CONCLUSIONS: There was significant deficit in tyrosine transport in BP compared to HC that was reversed by clozapine but not lithium. Clozapine was more effective when used alone than when added together with lithium. Potential clinical implications of this will be discussed.

Place, publisher, year, edition, pages
Springer, 2023
Keywords
Bipolar disorder, Clozapine, Dopamine, Fibroblasts, Lithium, Noradrenaline, Pathophysiology, Tyrosine
National Category
Psychiatry
Identifiers
urn:nbn:se:oru:diva-106378 (URN)10.1007/s00213-023-06397-5 (DOI)001008445200001 ()37318540 (PubMedID)2-s2.0-85161935180 (Scopus ID)
Funder
Örebro UniversityRegion Örebro County
Available from: 2023-06-26 Created: 2023-06-26 Last updated: 2025-08-06Bibliographically approved
Comasco, E., Vumma, R., Toffoletto, R., Johansson, J., Flyckt, L., Lewander, T., . . . Venizelos, N. (2017). Genetic and Functional Study of L-Type Amino Acid Transporter 1 in Schizophrenia. Neuropsychobiology, 74(2), 96-103
Open this publication in new window or tab >>Genetic and Functional Study of L-Type Amino Acid Transporter 1 in Schizophrenia
Show others...
2017 (English)In: Neuropsychobiology, ISSN 0302-282X, E-ISSN 1423-0224, Vol. 74, no 2, p. 96-103Article in journal (Refereed) Published
Abstract [en]

Schizophrenia involves neural catecholaminergic dysregulation. Tyrosine is the precursor of catecholamines, and its major transporter, according to studies on fibroblasts, in the brain is the L-type amino acid transporter 1 (LAT1). The present study assessed haplotype tag single-nucleotide polymorphisms (SNPs) of the SLC7A5/LAT1 gene in 315 patients with psychosis within the schizophrenia spectrum and 233 healthy controls to investigate genetic vulnerability to the disorder as well as genetic relationships to homovanillic acid (HVA) and 3-methoxy-4-hydroxyphenylglycol (MHPG), the major catecholamine metabolites in the cerebrospinal fluid (CSF). Moreover, the involvement of the different isoforms of the system L in tyrosine uptake and LAT1 tyrosine kinetics were studied in fibroblast cell lines of 10 patients with schizophrenia and 10 healthy controls. The results provide suggestive evidence of individual vulnerability to schizophrenia related to the LAT1 SNP rs9936204 genotype. A number of SNPs were nominally associated with CSF HVA and MHPG concentrations but did not survive correction for multiple testing. The LAT1 isoform was confirmed as the major tyrosine transporter in patients with schizophrenia. However, the kinetic parameters (maximal transport capacity, affinity of the binding sites, and diffusion constant of tyrosine transport through the LAT1 isoform) did not differ between patients with schizophrenia and controls. The present genetic findings call for independent replication in larger samples, while the functional study seems to exclude a role of LAT1 in the aberrant transport of tyrosine in fibroblasts of patients with schizophrenia.

Place, publisher, year, edition, pages
Basel: S. Karger, 2017
Keywords
Amino acid transporter light chain system L; Fibroblasts; L-Type amino acid transporter 1; Schizophrenia; Single-nucleotide polymorphism; Tyrosine
National Category
Psychiatry Psychology Neurology
Research subject
Psychiatry; Genetics; Biomedicine
Identifiers
urn:nbn:se:oru:diva-55674 (URN)10.1159/000455234 (DOI)000399488600008 ()28190014 (PubMedID)2-s2.0-85013072462 (Scopus ID)
Available from: 2017-02-14 Created: 2017-02-14 Last updated: 2025-08-06Bibliographically approved
Vumma, R., Johansson, J. & Venizelos, N. (2017). Proinflammatory Cytokines and Oxidative Stress Decrease the Transport of Dopamine Precursor Tyrosine in Human Fibroblasts. Neuropsychobiology, 75(4), 178-184
Open this publication in new window or tab >>Proinflammatory Cytokines and Oxidative Stress Decrease the Transport of Dopamine Precursor Tyrosine in Human Fibroblasts
2017 (English)In: Neuropsychobiology, ISSN 0302-282X, E-ISSN 1423-0224, Vol. 75, no 4, p. 178-184Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Proinflammatory cytokines and oxidative stress responses have been extensively implicated in the pathophysiology of neuropsychiatric disorders over the past 2 decades. Moreover, disturbed transport of the dopamine precursor (i.e., the amino acid tyrosine) has been demonstrated, in different studies, across fibroblast cell membranes obtained from neuropsychiatric patients. However, the role and influences of proinflammatory cytokines and oxidative stress, and the reasons for disturbed tyrosine transport in neuropsychiatric disorders, are still not evaluated.

AIMS: The present study aimed to assess the role of proinflammatory cytokines and oxidative stress, indicated in many neuropsychiatric disorders, in tyrosine transportation, by using human skin-derived fibroblasts.

METHODS: Fibroblasts obtained from a healthy control were used in this study. Fibroblasts were treated with proinflammatory cytokines (IL-1β, IFN-γ, IL-6, TNF-α), their combinations, and oxidative stress, optimized for concentrations and incubation time, to analyze the uptake of 14C-tyrosine compared to untreated controls.

RESULTS AND CONCLUSION: This study demonstrates that proinflammatory cytokines and oxidative stress decrease the transport of tyrosine (47% and 33%, respectively), which can alter dopamine synthesis. The functionality of the tyrosine transporter could be a new potential biomarker to target for discovering new drugs to counteract the effects of proinflammatory cytokines and oxidative stress in the pathophysiology of neuropsychiatric disorders.

Place, publisher, year, edition, pages
Basel: S. Karger, 2017
Keywords
Proinflammatory cytokines; Oxidative stress; Tyrosine transport; Dopamine precursor; Human fibroblasts; Neuropsychiatric disorders
National Category
Neurosciences Psychiatry
Identifiers
urn:nbn:se:oru:diva-64505 (URN)10.1159/000485130 (DOI)000431062500004 ()29339668 (PubMedID)2-s2.0-85040740113 (Scopus ID)
Funder
Swedish Research Council, K2007-62X-08318-20-3
Note

Funding Agency:

Ingrid Thuring Foundation 

Available from: 2018-01-25 Created: 2018-01-25 Last updated: 2025-08-06Bibliographically approved
Johansson, J., Landgren, M., Fernell, E., Lewander, T. & Venizelos, N. (2013). Decreased binding capacity (Bmax) of muscarinic acetylcholine receptors in fibroblasts from boys with attention-deficit/hyperactivity disorder (ADHD). ADHD Attention Deficit and Hyperactivity Disorders, 5(3), 267-271
Open this publication in new window or tab >>Decreased binding capacity (Bmax) of muscarinic acetylcholine receptors in fibroblasts from boys with attention-deficit/hyperactivity disorder (ADHD)
Show others...
2013 (English)In: ADHD Attention Deficit and Hyperactivity Disorders, ISSN 1866-6116, E-ISSN 1866-6647, Vol. 5, no 3, p. 267-271Article in journal (Refereed) Published
Abstract [en]

Monoaminergic dysregulation is implicated in attention-deficit/hyperactivity disorder (ADHD), and methylphenidate and amphetamines are the most frequently prescribed pharmacological agents for treating ADHD. However, it has recently been proposed that the core symptoms of the disorder might be due to an imbalance between monoaminergic and cholinergic systems. In this study, we used fibroblast cell homogenates from boys with and without ADHD as an extraneural cell model to examine the cholinergic receptor density, that is, muscarinic acetylcholine receptors (mAChRs). We found that the binding capacity (Bmax) of [³H] Quinuclidinyl benzilate (³H-QNB) to mAChRs was decreased by almost 50 % in the children with ADHD (mean = 30.6 fmol/mg protein, SD = 25.6) in comparison with controls [mean = 63.1 fmol/mg protein, SD = 20.5, p ≤ 0.01 (Student's unpaired t test)]. The decreased Bmax indicates a reduced cholinergic receptor density, which might constitute a biomarker for ADHD. However, these preliminary findings need to be replicated in larger ADHD and comparison cohorts

Place, publisher, year, edition, pages
Berlin, Germany: Springer Berlin/Heidelberg, 2013
Keywords
ADHD, Fibroblaster, Muscarinic acetylcholine receptor, Receptor binding assay, Biomarker
National Category
Medical and Health Sciences Psychiatry
Research subject
Psychiatry; Biomedicine
Identifiers
urn:nbn:se:oru:diva-42579 (URN)10.1007/s12402-013-0103-0 (DOI)000214425500002 ()23389940 (PubMedID)2-s2.0-84883061295 (Scopus ID)
Funder
Östergötland County Council, FoUcenter Dr 91021Swedish Research Council, K2007-62X-08318-20-3The Karolinska Institutet's Research Foundation
Available from: 2015-02-11 Created: 2015-02-11 Last updated: 2025-08-06Bibliographically approved
Engwall, M., Venizelos, N., Westman, O., Larsson, M., Nordén, M., Hollert, H. & Johansson, J. (2013). Polycyclic aromatic hydrocarbons (PAHs) reduce hepatic beta-oxidation of fatty acids in chick embryos. Environmental Science and Pollution Research, 20(3), 1881-1888
Open this publication in new window or tab >>Polycyclic aromatic hydrocarbons (PAHs) reduce hepatic beta-oxidation of fatty acids in chick embryos
Show others...
2013 (English)In: Environmental Science and Pollution Research, ISSN 0944-1344, E-ISSN 1614-7499, Vol. 20, no 3, p. 1881-1888Article in journal (Refereed) Published
Abstract [en]

Polycyclic aromatic hydrocarbons (PAHs) are widespread fused-ring contaminants formed during incomplete combustion of almost all kind of organic materials from both natural and anthropogenic sources. Some PAHs have been shown to be carcinogenic to humans, and a wide range of PAHs are found in wildlife all around the globe including avian species. The purpose of this project was to assess the effects of a standard mixture of 16 PAHs (United States Environmental Protection Agency) on the hepatic fatty acid beta-oxidation in chicken embryos (Gallus gallus domesticus) exposed in ovo. The hepatic beta-oxidation was measured using a tritium release assay with [9,10-H-3]-palmitic acid (16:0) as substrate. Treated groups were divided into groups of 0.05, 0.1, 0.3, 0.5, and 0.8 mg PAHs/kg egg weight. The hepatic beta-oxidation was reduced after exposure in ovo to the 16 PAHs mixture compared to control. The mechanisms causing reduced fatty acid oxidation in the present study are unclear, however may be due to deficient membrane structure, the functionality of enzymes controlling the rate of fatty acid entering into the mitochondria, or complex pathways connected to endocrine disruption. To the best of our knowledge, this is the first time a PAH-caused reduction of hepatic beta-oxidation of fatty acids in avian embryos has been observed. The implication of this finding on risk assessment of PAH exposure in avian wildlife remains to be determined.

National Category
Environmental Sciences
Research subject
Enviromental Science; Biology
Identifiers
urn:nbn:se:oru:diva-29081 (URN)10.1007/s11356-012-1418-7 (DOI)000315442500065 ()23274806 (PubMedID)2-s2.0-84874289064 (Scopus ID)
Projects
SOILTOX
Funder
Knowledge Foundation
Available from: 2013-05-21 Created: 2013-05-21 Last updated: 2025-08-06Bibliographically approved
Venizelos, N., Johansson, J., Landgren, M., Fernell, E. & Vumma, R. (2012). Altered tryptophan and alanine transport in cultured fibroblast from boys with attention deficit/hyperactivity disorder (ADHD). Paper presented at the 28th CINP World Congress of Neuropsychopharmacology, Stockholm, Sweden, 3–7 June 2012.. International Journal of Neuropsychopharmacology, 15(s1), 224-224, Article ID P-17-014.
Open this publication in new window or tab >>Altered tryptophan and alanine transport in cultured fibroblast from boys with attention deficit/hyperactivity disorder (ADHD)
Show others...
2012 (English)In: International Journal of Neuropsychopharmacology, ISSN 1461-1457, E-ISSN 1469-5111, Vol. 15, no s1, p. 224-224, article id P-17-014Article in journal, Meeting abstract (Refereed) Published
Abstract [en]

Background: The amino acid tyrosine is the precursor for the synthesis of the neurotransmitters dopamine and norepinephrine, while tryptophan is the precursor of serotonin. These neurotransmitters are implicated in the pathophysiology of Attention Deficit/Hyperactivity Disorder (ADHD). A disturbed transport of tyrosine, as well as other amino acids, has been found in a number of other neuropsychiatric disorders, such as schizophrenia, bipolar disorder and autism, when using the fibroblast cell model. Hence, the aim of this study was to explore whether children with ADHD may have disturbed amino acid transport. 

Materials and Methods: Skin biopsies from 14 boys diagnosed with ADHD and from 13 matching boys without a diagnosis of a developmental disorder were obtained, and from the biopsies were primary fibroblast cell lines derived. The transport of the amino acids tyrosine, tryptophan and alanine across the fibroblast cell membranes was measured by the cluster tray method. The kinetic parameters, maximal transport capacity (Vmax) and affinity constant (Km) were determined. Student’s unpaired t-test or the Mann Whitney U test was used to analyze any difference between the two groups.

Results: The tryptophan transport (Vmax) was significantly decreased in the ADHD group in comparison to controls (p=0.039), while the alanine transport (Vmax) was significantly increased in the ADHD group (p=0.031). There was no significant difference regarding the tyrosine transport between the two groups.

Conclusions: A decreased transport capacity of tryptophan implies that less tryptophan is being transported across the BBB in the ADHD group, since tryptophan uses the same transport systems in both fibroblasts and at the blood brain barrier (BBB). This could lead to deficient serotonin access in the brain that might cause disturbances in both the serotonergic and the catecholaminergic neurotransmitter systems, since these systems are highly interconnected. The physiological importance of an elevated transport capacity of alanine to the brain is not known to date.

Place, publisher, year, edition, pages
New York, USA: Cambridge University Press, 2012
National Category
Medical and Health Sciences Neurology Psychiatry
Research subject
Psychiatry; Biomedicine
Identifiers
urn:nbn:se:oru:diva-42595 (URN)000209062500815 ()
Conference
the 28th CINP World Congress of Neuropsychopharmacology, Stockholm, Sweden, 3–7 June 2012.
Note

Det står E. Elisabeth i publikationenen men det bör stå Elisabeth Fernell som var ifyllt i posten från början så detta har fått stå kvar./vf

Available from: 2015-02-11 Created: 2015-02-11 Last updated: 2025-08-06Bibliographically approved
Venizelos, N., Johansson, J., Landgren, M., Fernell, E. & Lewander, T. (2012). Decreased density of muscarinic acetylcholine receptors in fibroblast from boys with attention deficit/hyperactivity disorder (ADHD): An in vitro study. Paper presented at the 28th CINP World Congress of Neuropsychopharmacology, Stockholm, Sweden, 3–7 June 2012.. International Journal of Neuropsychopharmacology, 15(s1), 224-224, Article ID P-17-015.
Open this publication in new window or tab >>Decreased density of muscarinic acetylcholine receptors in fibroblast from boys with attention deficit/hyperactivity disorder (ADHD): An in vitro study
Show others...
2012 (English)In: International Journal of Neuropsychopharmacology, ISSN 1461-1457, E-ISSN 1469-5111, Vol. 15, no s1, p. 224-224, article id P-17-015Article in journal, Meeting abstract (Refereed) Published
Abstract [en]

Background: It is believed that the neurotransmitters, dopamine and norepinephrine are involved in the pathophysiology of the neurobehavioral disorder Attention Deficit/Hyperactivity Disorder (ADHD). Moreover, it is known that cholinergic activity can modulate dopaminergic activity in the brain. The aim of this study was to measure the density and affinity of muscarinic acetylcholine receptors (mAChRs) in children with ADHD, by using the fibroblast cell model.

Methods: Fibroblast cell homogenates from 11 boys with ADHD, fulfilling the DSM-IV diagnostic criteria and from 9 matching controls were used in the study. Radioligand binding assay was used to determine the maximal binding capacity (Bmax) and the equilibrium dissociation constant (KD) of mAChRs, using the mAChR antagonist 3H-QNB. Due to non-normally distribution of the calculated data, three outliers were identified by the MADE method (two in the ADHD group, both with a non-hereditary ADHD and one in the comparison group), and were therefore excluded from the statistical analyses.

Results: A significantly lower Bmax for the binding of the muscarinic antagonist 3H-QNB was observed in the fibroblasts from the children with ADHD (n=9) when compared to controls (n=8) (p=0.01), but the KD did not differ between the two groups (p=0.40).

Conclusions:The present results indicate a reduced density of mAChR in fibroblasts from children with a hereditary ADHD, which might be an indicator of the disorder. However, further studies are needed to confirm these observations.

Place, publisher, year, edition, pages
New York, USA: Cambridge University Press, 2012
Keywords
ADHD, Dopamine, Muscarinic receptor, Receptor binding assay, Fibroblast cells
National Category
Medical and Health Sciences Neurology Psychiatry
Research subject
Psychiatry; Biomedicine
Identifiers
urn:nbn:se:oru:diva-42596 (URN)000209062500816 ()
Conference
the 28th CINP World Congress of Neuropsychopharmacology, Stockholm, Sweden, 3–7 June 2012.
Available from: 2015-02-11 Created: 2015-02-11 Last updated: 2025-08-06Bibliographically approved
Johansson, J., Landgren, M., Fernell, E., Vumma, R., Ahlin, A., Bjerkenstedt, L. & Venizelos, N. (2011). Altered tryptophan and alanine transport in fibroblasts from boys with attention-deficit/hyperactivity disorder (ADHD): an in vitro study. Behavioral and Brain Functions, 7, 40
Open this publication in new window or tab >>Altered tryptophan and alanine transport in fibroblasts from boys with attention-deficit/hyperactivity disorder (ADHD): an in vitro study
Show others...
2011 (English)In: Behavioral and Brain Functions, E-ISSN 1744-9081, Vol. 7, p. 40-Article in journal (Refereed) Published
Abstract [en]

Background: The catecholaminergic and serotonergic neurotransmitter systems are implicated in the pathophysiology of attention-deficit/hyperactivity disorder (ADHD). The amino acid tyrosine is the precursor for synthesis of the catecholamines dopamine and norepinephrine, while tryptophan is the precursor of serotonin. A disturbed transport of tyrosine, as well as other amino acids, has been found in a number of other psychiatric disorders, such as schizophrenia, bipolar disorder and autism, when using the fibroblast cell model. Hence, the aim of this study was to explore whether children with ADHD may have disturbed amino acid transport. Methods: Fibroblast cells were cultured from skin biopsies obtained from 14 boys diagnosed with ADHD and from 13 matching boys without a diagnosis of a developmental disorder. Transport of the amino acids tyrosine, tryptophan and alanine across the cell membrane was measured by the cluster tray method. The kinetic parameters, maximal transport capacity (V(max)) and affinity constant (K(m)) were determined. Any difference between the two groups was analyzed by Student's unpaired t-test or the Mann Whitney U test. Results: The ADHD group had significantly decreased V(max) (p = 0.039) and K(m) (increased affinity) (p = 0.010) of tryptophan transport in comparison to controls. They also had a significantly higher V(max) of alanine transport (p = 0.031), but the Km of alanine transport did not differ significantly. There were no significant differences in any of the kinetic parameters regarding tyrosine transport in fibroblasts for the ADHD group. Conclusions: Tryptophan uses the same transport systems in both fibroblasts and at the blood brain barrier (BBB). Hence, a decreased transport capacity of tryptophan implies that less tryptophan is being transported across the BBB in the ADHD group. This could lead to deficient serotonin access in the brain that might cause disturbances in both the serotonergic and the catecholaminergic neurotransmitter systems, since these systems are highly interconnected. The physiological importance of an elevated transport capacity of alanine to the brain is not known to date.

National Category
Medical and Health Sciences
Research subject
Biomedicine
Identifiers
urn:nbn:se:oru:diva-20854 (URN)10.1186/1744-9081-7-40 (DOI)000295870400001 ()2-s2.0-80053171785 (Scopus ID)
Available from: 2012-01-11 Created: 2012-01-11 Last updated: 2025-08-06Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0009-0007-2285-1227

Search in DiVA

Show all publications